Stock listing
Tradegate:DP8 CervoMed Inc. Aktie
German listing (Tradegate) of CervoMed Inc. · home listing NASDAQ:CRVO
Follow CervoMed Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CRVO
$1.46 USD +0.01 (+0.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRVO
- Day range
- $1.40 – $1.65 USDNov 20, 2026
- Volume
- 1.18M sharesNov 20, 2026
- Market cap
- $22.09M USDAt the close on Nov 20, 2026 · price × 15.13M shares outstanding
- 52-week range
- $1.27 – $10.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.00M USDMedian day 234,572 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRVO · Home | $1.46 USD | +0.01 (+0.7%) | 1,183,199 | $1.53 | $1.65 | $1.401 | $1.45 | Close on Nov 20, 2026 |
| Frankfurt:DP8 | €1.18 EUR | -0.12 (-9.2%) | — | €1.18 | €1.18 | €1.18 | €1.30 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRVO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.46 | +0.01 | +0.7% | $1.53 | $1.65 | $1.401 | 1,183,199 | |
| $1.45 | -0.05 | -3.3% | $1.50 | $1.575 | $1.45 | 295,166 | |
| $1.50 | -0.17 | -10.2% | $1.63 | $1.69 | $1.50 | 335,686 | |
| $1.67 | -0.02 | -1.2% | $1.69 | $1.90 | $1.645 | 530,807 | |
| $1.69 | -0.14 | -7.7% | $1.75 | $1.79 | $1.64 | 631,908 | |
| $1.83 | +0.06 | +3.4% | $1.83 | $2.20 | $1.73 | 3,175,167 | |
| $1.77 | +0.40 | +29.2% | $1.40 | $2.09 | $1.38 | 9,990,746 | |
| $1.37 | -0.06 | -4.2% | $1.39 | $1.43 | $1.295 | 195,559 | |
| $1.43 | +0.01 | +0.7% | $1.39 | $1.45 | $1.34 | 315,195 | |
| $1.42 | -0.03 | -2.1% | $1.46 | $1.519 | $1.27 | 587,078 | |
| $1.45 | -0.11 | -7.1% | $1.55 | $1.59 | $1.45 | 311,108 | |
| $1.56 | +0.01 | +0.6% | $1.55 | $1.68 | $1.46 | 426,565 | |
| $1.55 | -0.09 | -5.5% | $1.64 | $1.70 | $1.52 | 358,128 | |
| $1.64 | +0.04 | +2.5% | $1.61 | $1.71 | $1.56 | 286,870 | |
| $1.60 | -0.15 | -8.6% | $1.71 | $1.77 | $1.60 | 585,339 | |
| $1.75 | -0.46 | -20.8% | $2.17 | $2.18 | $1.66 | 1,168,877 | |
| $2.21 | -0.01 | -0.5% | $2.21 | $2.27 | $2.14 | 201,600 | |
| $2.22 | -0.02 | -0.9% | $2.215 | $2.30 | $2.18 | 150,558 | |
| $2.24 | -0.07 | -3.0% | $2.29 | $2.29 | $2.18 | 103,966 | |
| $2.31 | +0.07 | +3.1% | $2.23 | $2.33 | $2.22 | 111,783 | |
| $2.24 | -0.10 | -4.3% | $2.29 | $2.35 | $2.23 | 97,663 | |
| $2.34 | +0.05 | +2.2% | $2.31 | $2.41 | $2.31 | 79,257 | |
| $2.29 | -0.02 | -0.9% | $2.28 | $2.406 | $2.28 | 136,346 | |
| $2.31 | +0.07 | +3.1% | $2.24 | $2.35 | $2.18 | 206,704 | |
| $2.24 | -0.01 | -0.4% | $2.23 | $2.30 | $2.22 | 98,726 | |
| $2.25 | -0.04 | -1.7% | $2.26 | $2.31 | $2.213 | 201,191 | |
| $2.29 | +0.02 | +0.9% | $2.22 | $2.41 | $2.13 | 497,193 | |
| $2.27 | -0.24 | -9.6% | $2.50 | $2.53 | $2.17 | 542,057 | |
| $2.51 | -0.71 | -22.0% | $2.75 | $2.79 | $2.42 | 892,095 | |
| $3.22 | -0.06 | -1.8% | $3.26 | $3.335 | $3.166 | 237,328 | |
| $3.28 | +0.10 | +3.1% | $3.15 | $3.31 | $3.13 | 341,949 | |
| $3.18 | -0.16 | -4.8% | $3.26 | $3.36 | $3.13 | 309,461 | |
| $3.34 | +0.03 | +0.9% | $3.36 | $3.44 | $3.11 | 470,492 | |
| $3.31 | +0.29 | +9.6% | $3.13 | $3.35 | $3.06 | 648,749 | |
| $3.02 | +0.09 | +3.1% | $2.96 | $3.07 | $2.881 | 241,802 | |
| $2.93 | -0.04 | -1.3% | $2.98 | $2.98 | $2.86 | 175,071 | |
| $2.97 | +0.09 | +3.1% | $2.91 | $3.05 | $2.75 | 375,542 | |
| $2.88 | +0.21 | +7.9% | $2.70 | $2.92 | $2.67 | 455,792 | |
| $2.67 | +0.13 | +5.1% | $2.55 | $2.68 | $2.54 | 171,059 | |
| $2.54 | +0.02 | +0.8% | $2.52 | $2.63 | $2.52 | 106,090 | |
| $2.52 | +0.01 | +0.4% | $2.46 | $2.53 | $2.43 | 91,009 | |
| $2.51 | -0.02 | -0.8% | $2.59 | $2.60 | $2.50 | 123,577 | |
| $2.53 | +0.12 | +5.0% | $2.43 | $2.61 | $2.42 | 260,726 | |
| $2.41 | -0.02 | -0.8% | $2.47 | $2.49 | $2.41 | 109,104 | |
| $2.43 | -0.12 | -4.7% | $2.53 | $2.575 | $2.43 | 180,861 | |
| $2.55 | +0.11 | +4.5% | $2.53 | $2.601 | $2.48 | 119,434 | |
| $2.44 | -0.01 | -0.4% | $2.45 | $2.519 | $2.40 | 100,328 | |
| $2.45 | -0.08 | -3.2% | $2.53 | $2.53 | $2.43 | 106,984 | |
| $2.53 | -0.04 | -1.6% | $2.54 | $2.58 | $2.49 | 128,295 | |
| $2.57 | +0.09 | +3.6% | $2.54 | $2.64 | $2.50 | 234,572 | |
| $2.48 | -0.03 | -1.2% | $2.50 | $2.53 | $2.47 | 114,864 | |
| $2.51 | -0.02 | -0.8% | $2.53 | $2.54 | $2.47 | 156,009 | |
| $2.53 | -0.03 | -1.2% | $2.58 | $2.58 | $2.42 | 393,938 | |
| $2.56 | +0.02 | +0.8% | $2.54 | $2.58 | $2.52 | 108,604 | |
| $2.54 | -0.10 | -3.8% | $2.66 | $2.665 | $2.52 | 199,035 | |
| $2.64 | +0.07 | +2.7% | $2.55 | $2.65 | $2.55 | 134,532 | |
| $2.57 | -0.06 | -2.3% | $2.58 | $2.67 | $2.55 | 183,584 | |
| $2.63 | +0.03 | +1.2% | $2.56 | $2.64 | $2.55 | 94,998 | |
| $2.60 | -0.04 | -1.5% | $2.64 | $2.67 | $2.55 | 264,545 | |
| $2.64 | -0.01 | -0.4% | $2.65 | $2.67 | $2.61 | 112,169 | |
| $2.65 | 0.00 | 0.0% | $2.61 | $2.67 | $2.601 | 93,644 | |
| $2.65 | +0.02 | +0.8% | $2.69 | $2.73 | $2.60 | 220,453 | |
| $2.63 | +0.01 | +0.4% | $2.65 | $2.65 | $2.57 | 288,040 | |
| $2.62 | +0.06 | +2.3% | $2.60 | $2.64 | $2.56 | 269,568 | |
| $2.56 | -0.15 | -5.5% | $2.70 | $2.71 | $2.50 | 417,323 |
Splits
5 splits since 2014 · NASDAQ:CRVO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-3 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-100 | Consolidation |
- Ticker
- Tradegate:DP8
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Tradegate
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
Latest deck · March 2026
AD/PD 2026
Conference · 18 slides
Latest news
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
Nov 16, 2026
Closed $1.50 (-10.2%) on Nov 17, 2026
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Nov 9, 2026
Closed $1.43 (+0.7%) on Nov 9, 2026
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Oct 29, 2026
Closed $1.75 (-20.8%) on Oct 29, 2026
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
Oct 12, 2026
Closed $2.51 (-22.0%) on Oct 12, 2026
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Sep 28, 2026
Closed $2.67 (+5.1%) on Sep 28, 2026
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Sep 22, 2026
Closed $2.53 (+5.0%) on Sep 22, 2026
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Sep 10, 2026
Closed $2.48 (-1.2%) on Sep 10, 2026
CervoMed to Participate in September Investor Conferences
Sep 8, 2026
Closed $2.53 (-1.2%) on Sep 8, 2026
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 10, 2026
Closed $2.86 (-0.3%) on Aug 10, 2026
CervoMed Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 79 in all · newest Nov 16, 2026 · oldest 2023
- Decks
- 16 decks · latest March 2026
Where CervoMed Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRVO · Home listing | NASDAQ | United States | USD |
| LS Exchange:A3ES01 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3ES01 | Lang & Schwarz | Germany | EUR |
| BOATS:CRVO | BOATS | United States | USD |
| Tradegate:DP8 · This page | Tradegate | Germany | EUR |
| Frankfurt:DP8 | Frankfurt | Germany | EUR |
| Stuttgart:DP8 | Stuttgart | Germany | EUR |
Valuation
EV/sales 285× against a median of 46.1×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.49M USD
- P/E
- Loss
- EV/sales
- 285×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.3×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.97
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CervoMed Inc. · NASDAQ:CRVO | US$22.09M | US$2.49M | n/a | 285× | n/a | 1.3× | n/a | 0.0× | 1.97 |
| Actinogen Medical Limited · ASX:ACW | US$23.08M | US$15.17M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.72M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| ME Therapeutics Holdings, Inc. · CSE:METX | US$22.25M | US$21.88M | n/a | n/a | n/a | 49.5× | n/a | 0.0× | 0.52 |
| Sona Nanotech, Inc. · CSE:SONA | US$21.84M | US$22.06M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Mendus AB · OMXSTO:IMMU | US$21.76M | US$17.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | n/a |
| Metagenomi Therapeutics, Inc. · NASDAQ:MGX | US$21.36M | −US$44.10M | n/a | −6.2× | n/a | 0.2× | n/a | 0.4× | 1.65 |
| NanoGroup SA · GPW:NNG | US$21.32M | US$18.78M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Cel-Sci Corporation · AMEX:CVM | US$21.28M | US$14.76M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.13 |
| ZYUS Life Sciences Corporation · TSXV:ZYUS | US$20.92M | US$25.65M | n/a | 98.4× | n/a | n/a | n/a | n/a | -0.02 |
| Median of the others | US$21.80M | US$18.22M | 46.1× | 1.6× | 0.0× | 0.52 |
Forecasts
6 strong buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.13 · 5 analysts
- Revenue, year to Dec 2026
- 133.3K · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| John Alam | Co-Founder and Chief Executive Officer |
| William Elder | Chief Financial Officer and General Counsel |
| PJ Kelleher | Investor Relations |
| Kelly Blackburn | Executive Vice President, Clinical Development |
| Marco Verwijs | Executive Vice President, Technical Operations |
| Mark De Rosch | Executive Vice President, Regulatory and Government Affairs, and Program Management |
| Matthew Winton | Chief Commercial and Business Officer |
| Sylvie Grégoire | Co-Founder |
Board
| Director | Role |
|---|---|
| Joshua Boger | Chair Of The Board |
| David Quigley | Senior Partner |
| Frank Zavrl | Director |
| Jane H. Hollingsworth | Director |
| Jeff Poulton | Director |
| John Alam | Co-Founder and Chief Executive Officer |
| Marwan Sabbagh | Director |
| Sylvie Grégoire | Co-Founder |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · After close | +0.7% |
| Q2 2026 | Aug 7, 2026 | +3.6% |
| Q1 2026 | May 19, 2026 | +6.6% |
| Q4 2025 | Mar 13, 2026 · After close | +1.4% |
| Q3 2025 | Nov 7, 2025 · After close | −0.3% |
| Q2 2025 | Aug 8, 2025 · Before open | +5.5% |
| Q1 2025 | Jun 13, 2025 · After close | +2.0% |
| Q4 2024 | Mar 17, 2025 · Before open | +40.5% |
| Q3 2024 | Nov 12, 2024 · Before open | −2.5% |
| Q2 2024 | Aug 9, 2024 · After close | +7.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +0.1% |
| Q4 2023 | Mar 29, 2024 · After close | −2.6% |
| Q3 2023 | Nov 13, 2023 · Before open | −1.2% |
| Q2 2023 | Aug 8, 2023 · After close | −3.5% |
| Q1 2023 | May 15, 2023 · Before open | −2.2% |
| Q4 2022 | Mar 21, 2023 | −2.5% |
| Q3 2022 | Nov 14, 2022 | +21.5% |
| Q2 2022 | Aug 11, 2022 | −2.0% |
| Q1 2022 | May 12, 2022 | +18.6% |
| Q4 2021 | Mar 21, 2022 | −3.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AD/PD 2026 | Conference | 18 slides | March 2026 |
| CTAD 2025 | Conference | 25 slides | Dec 4, 2025 |
| Conference Presentation (June 2025) | Conference | 20 slides | June 2025 |
| Technical Presentation (January 2025) | Technical | 22 slides | Jan 31, 2025 |
| Investor Presentation (December 2024) | Investor deck | 13 slides | Dec 10, 2024 |
| Investor Presentation (October 2023) | Investor deck | 25 slides | Oct 25, 2023 |
| Technical Presentation (October 2023) | Technical | 22 slides | Oct 25, 2023 |
| Investor Presentation (September 2023) | Investor deck | 20 slides | Sep 6, 2023 |
| Diffusion Pharmaceuticals — Canaccord Growth Conference 2023 | Conference | 20 slides | Aug 9, 2023 |
| Diffusion Pharmaceuticals — Merger or Acquisition (May 2023) | Merger or acquisition | 26 slides | May 15, 2023 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| EIP Pharma — Merger or Acquisition (March 2023) | Merger or acquisition | 25 slides | Mar 30, 2023 |
| Diffusion Pharmaceuticals — Investor Presentation (September 2020) | Investor deck | 29 slides | Sep 15, 2020 |
| Diffusion Pharmaceuticals — Technical Presentation (December 2019) | Technical | 25 slides | Dec 10, 2019 |
| CTAD 2019 | Conference | 19 slides | December 2019 |
| Diffusion Pharmaceuticals — Investor Presentation (May 2017) | Investor deck | 40 slides | May 22, 2017 |
| Diffusion Pharmaceuticals — Investor Presentation (January 2017) | Investor deck | 45 slides | Jan 27, 2017 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock Closed: US$10M raised · US$4 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Jun 22, 2026 |
| Registered direct offering of common stock Announced: US$10M · US$4 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Jun 18, 2026 |
| Private placement of units (common stock or pre-funded warrant, Series B warrant and Series C warrant) Announced: about US$10.5M · US$3.14 a unit · Warrants at US$3.32 Buyers: Joshua S. Boger; Trusts related to John J. Alam and Sylvie Grégoire Insiders: Supported by insiders including board chair Joshua S. Boger and trusts related to CEO John J. Alam and director Sylvie Grégoire Use of proceeds: Research and development of neflamapimod, working capital and general corporate purposes | Jun 10, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.01M | 9.74M | 7.14M | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 18.8M | 8.44M | 1.34M | 93.4K | 103.2K | 97.9K | 110.4K | 68.0K | 25.3K | |
| Gross profit | -9.06M | -1.29M | -1.34M | -93.4K | -103.2K | -97.9K | -110.0K | -68.0K | -25.3K | |
| Research and development | 21.8M | 18.8M | 8.44M | 1.34M | 8.50M | 9.43M | 6.62M | 5.75M | 5.09M | 7.25M |
| Selling, general and administrative | 10.5M | 9.17M | 6.52M | 8.74M | 7.45M | 6.44M | 5.42M | |||
| Operating income | -28.3M | -18.2M | -7.81M | -3.48M | -24.7M | -16.0M | -11.6M | -19.0M | -11.3M | -18.4M |
| Depreciation and amortization | 1.94M | 5 | 0 | 93.4K | 103.2K | 97.9K | 110.4K | 68.0K | 25.3K | |
| EBITDA | -16.3M | -7.81M | -3.48M | -24.6M | -15.9M | -11.5M | -18.8M | -11.3M | -18.3M | |
| Interest expense | 0 | 587 | 3.00K | 100.0K | 37.0K | |||||
| Income before tax | -27.0M | -16.3M | -2.17M | -15.6M | -24.5M | -15.9M | -11.5M | -18.8M | -2.42M | -18.4M |
| Income tax | 0 | 800.0K | 0 | -443.9K | -1.68M | 332.9K | -437.3K | -1.06M | -364.8K | |
| Net income | -27.0M | -16.3M | -2.17M | -5.80M | -24.1M | -14.2M | -11.8M | -18.4M | -1.36M | -18.0M |
| Earnings per share, basic | -2.98 | -2.02 | -0.82 | -11.20 | -12.38 | -0.30 | -1.76 | -8.21 | -3.16 | -1.76 |
| Earnings per share, diluted | 2,038,891.00 | 1,946,859.00 | 53,831,973.00 | 6,706,509.00 | 3,242,301.00 | -29.11 | -1.76 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.24M | 9.00M | 7.79M | 4.09M | 37.3M | 18.5M | 14.2M | 7.99M | 8.90M | 1.55M |
| Short-term investments | 12.6M | 29.9M | 0 | 12.4M | 0 | |||||
| Receivables | 427.0K | 2.25M | 915.4K | 69.6K | ||||||
| Current assets | 22.9M | 43.1M | 9.96M | 4.16M | 37.8M | 18.8M | 14.6M | 8.91M | 9.67M | 1.60M |
| Property, plant and equipment | 0 | 149.2K | 252.4K | 350.3K | 460.7K | 79.8K | ||||
| Goodwill | 0 | 6.93M | 6.93M | |||||||
| Total assets | 22.9M | 43.1M | 9.97M | 4.16M | 37.8M | 27.7M | 24.1M | 18.2M | 26.1M | 17.5M |
| Accounts payable | 1.45M | 1.51M | 662.5K | 97.3K | 947.5K | 545.8K | 1.25M | 198.8K | 512.0K | 1.68M |
| Current liabilities | 4.66M | 3.88M | 2.60M | 13.2M | 2.93M | 2.44M | 1.72M | 804.0K | 2.69M | 4.44M |
| Total debt | 12.4M | 10.0M | 149.2K | 247.0K | 550.0K | 2.43M | ||||
| Total liabilities | 4.66M | 3.88M | 2.60M | 13.2M | 2.93M | 2.92M | 3.98M | 2.59M | 4.92M | 8.30M |
| Shareholders' equity | 18.2M | 39.2M | 7.38M | -33.3M | 34.9M | 24.8M | 20.1M | 15.6M | 21.2M | 9.18M |
| Shares outstanding | 9.25M | 8.70M | 5.67M | 518.1K | 2.04M | 64.0M | 33.5M | 3.38M | 968.0K | 10.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.4M | -16.5M | -7.45M | -2.57M | -14.5M | -13.6M | -9.86M | -10.8M | -12.3M | -10.8M |
| Capital spending | 0 | -3 | -3 | -1 | 0 | 0 | 0 | 0 | -447.8K | -2.33K |
| Free cash flow | -23.4M | -16.5M | -7.45M | -2.57M | -14.5M | -13.6M | -9.86M | -10.8M | -12.8M | -10.8M |
| Cash from investing | 18.1M | -28.7M | 0 | -12.2M | 4.00K | 0 | -447.8K | 8.50M | ||
| Cash from financing | 4.59M | 46.4M | 11.1M | 0 | 33.3M | 17.9M | 16.0M | 9.87M | 20.1M | 1.83M |
| Change in cash | -764.0K | 1.21M | 3.70M | -2.57M | 18.8M | 4.34M | 6.19M | -905.3K | 7.34M | -444.3K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 9, 2026 | Current report | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Current report | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 13, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jul 10, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 9, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Jul 6, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jun 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 18, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 9, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 18, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 11, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 22, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 7, 2026 | Current report | SEC |
| 8-K · Current report | Mar 23, 2026 | Current report | SEC |
| 8-K · Current report | Mar 19, 2026 | Current report | SEC |
| 8-K · Current report | Mar 17, 2026 | Results | SEC |
| 10-K · Annual report | Mar 13, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| 8-K · Current report | Feb 18, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Nov 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 8-K · Current report | Oct 29, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 8-K · Current report | Oct 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 12, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Current report | SEC |
| 8-K · Current report | Jul 28, 2025 | Current report | SEC |
| 8-K · Current report | Jun 25, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Current report | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | May 12, 2025 | Offer document | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 18, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Current report | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 31, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 8-K · Current report | Nov 27, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| 8-K · Current report | Oct 30, 2024 | Current report | SEC |
| 8-K · Current report | Oct 16, 2024 | Current report | SEC |
| 424B3 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 11, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Oct 10, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 8, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 8, 2024 | Other filings | SEC |
| S-3 · Registration statement | Oct 3, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Oct 3, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 3, 2024 | Current report | SEC |
| 424B3 · Prospectus | Oct 1, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 15, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Aug 9, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Aug 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | Aug 1, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 1, 2024 | Current report | SEC |
| 8-K · Current report | Jul 23, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jul 12, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 14, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 424B3 · Prospectus | Jun 6, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 30, 2024 | Offer document | SEC |
| 8-K · Current report | May 20, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | May 16, 2024 | Other filings | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| S-1 · Registration statement | May 10, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Apr 11, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 5, 2024 | Results | SEC |
| 8-K · Current report | Apr 4, 2024 | Current report | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 18, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 5, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 28, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 28, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 7, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 2, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from CervoMed Inc.’s releases · as of Nov 4, 2026
- Common shares
- 15,128,540
- Fully diluted
- 15,128,540
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 15,128,540 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 15,128,540 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sol J. Barer Other companies: Teva Pharmaceutical Industries Limited (Director · Since at least Jan 1, 2018); NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Avalo Therapeutics, Inc. (Director · Feb 3, 2020 – Jun 15, 2021 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); Aevi Genomic Medicine LLC (Director · Jun 30, 2012 – Feb 3, 2020 · Past); InspireMD Inc. (Director · Jul 11, 2011 – Dec 7, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · May 1, 2011 – Nov 29, 2016 · Past); Amicus Therapeutics Inc (Director · Jan 6, 2009 – Jun 9, 2016 · Past); Celgene Corporation (Director · Dec 31, 2005 – Jan 13, 2011 · Past) | Director · Nov 1, 2013 – Jul 24, 2014 · Past |
| Isaac Blech Other companies: X4 Pharmaceuticals, Inc. (Director · Mar 13, 2019 – Mar 13, 2019 · Past); Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Aug 13, 2018 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past) | Director · Jul 24, 2014 – Aug 31, 2016 · Past |
| Phillip Donenberg Other companies: Sensei Biotherapeutics, Inc. (Chair of the Audit Committee · Since at least Feb 13, 2026); Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2018); Depomed Inc (SVP and CFO · Jul 16, 2018 – Jul 16, 2018 · Past); AveXis Inc (Chief Financial Officer · Oct 19, 2017 – May 15, 2018 · Past); ANI Pharmaceuticals, Inc. (Sr VP of Finance, CFO, Secy · Mar 16, 2006 – Jan 25, 2012 · Past) | Director · May 27, 2014 – Jul 24, 2014 · Past |
| Robert R. Ruffolo Other companies: LB Pharmaceuticals Inc (Independent Director · Since at least Sep 10, 2025); Elicio Therapeutics, Inc. (Director · Since at least Jun 1, 2023); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Dec 5, 2022 · Past) | Director · Jun 29, 2017 – Jun 14, 2018 · Past |
| Alan Levin Other companies: BioCryst Pharmaceuticals, Inc. (Director · Since at least Feb 27, 2020); Aceto Corporation (Director · Dec 5, 2013 – Oct 1, 2019 · Past); Pfizer, Inc. (Senior Vice President · Dec 30, 2005 – Sep 14, 2007 · Past) | Director · Jan 8, 2016 – Jul 1, 2021 · Past |
| Eric Francois Other companies: 60 Degrees Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); CERo Therapeutics Holdings, Inc. (Director · Since at least Feb 13, 2026); Scynexis, Inc. (Chief Financial Officer · Nov 1, 2015 – Jan 29, 2021 · Past) | Director · Jun 25, 2021 – Jul 1, 2021 · Past |
| Sylvie Grégoire Other companies: Revvity, Inc. (Director · Feb 6, 2015 – May 15, 2023 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Jun 14, 2007 · Past); Cubist Pharmaceuticals Inc (Director · Jun 9, 2006 – Jun 10, 2010 · Past) | Co-Founder · Since at least Aug 16, 2023 |
| Jeffrey V Poulton Other companies: Alnylam Pharmaceuticals, Inc. (EVP, Chief Financial Officer · Since at least Aug 13, 2019); Q32 Bio Inc. (Director · Jul 21, 2020 – Jun 14, 2023 · Past) | Director · Since at least Aug 16, 2023 |
| John Alam Other companies: Pathfinder Cell Therapy Inc (Director · Sep 2, 2011 – Sep 2, 2011 · Past); Vertex Pharmaceuticals Incorporated (EVP, Med. Dev. Group & CMO · Dec 20, 2005 – Oct 1, 2008 · Past) | Co-Founder and Chief Executive Officer · Since at least Aug 16, 2023 |
| Stephen M. Simes Other companies: CytoDyn Inc. (Director · Since at least Oct 13, 2022); ANI Pharmaceuticals, Inc. (Vice Chairman, President & CEO, Director · Dec 14, 2007 – Jan 25, 2012 · Past) | Chief Executive Officer, Director · Mar 5, 2014 – Jul 24, 2014 · Past |
All 40 people
| Person | Seat |
|---|---|
| Frank Zavrl Other companies: Puma Biotechnology Inc (Director · Sep 8, 2015 – Jun 9, 2020 · Past) | Director · Since at least Aug 16, 2023 |
| Glenn Golenberg Other companies: Grill Concepts Inc (Director · Jun 21, 2006 – Jun 12, 2008 · Past) | Director · Apr 30, 2009 – Apr 30, 2009 · Past |
| Jane H. Hollingsworth Other companies: NuPathe Inc. (Chief Executive Officer, Director · Aug 5, 2010 – Mar 8, 2012 · Past) | Director · Since at least Sep 1, 2020 |
| Jeff Poulton Other companies: Alnylam Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Nov 4, 2026) | Director · Since at least Nov 4, 2026 |
| Joshua Boger Other companies: Vertex Pharmaceuticals Incorporated (Director · Feb 2, 2006 – Jun 8, 2017 · Past) | Chair Of The Board · Since at least Feb 7, 2024 |
| Kelly Blackburn Other companies: aTyr Pharma, Inc. (VP, Clinical Affairs · May 6, 2015 – Mar 28, 2016 · Past) | Executive Vice President, Clinical Development · Since at least Aug 16, 2023 |
| Matthew Winton Other companies: Inozyme Pharma Inc (COO · Since at least Mar 13, 2024) | Chief Commercial and Business Officer · Since at least Oct 6, 2025 |
| Rex Bright Other companies: VYNE Therapeutics Inc. (Director · Jul 19, 2021 – Jul 19, 2021 · Past) | Director · Feb 5, 2014 – Jul 24, 2014 · Past |
| William Karl Hornung Other companies: Hepion Pharmaceuticals, Inc. (Chief Financial Officer · Jun 23, 2014 – Jun 4, 2015 · Past) | Chief Financial Officer · Sep 21, 2018 – Jan 27, 2022 · Past |
| Ben Shealy | Sr VP Finance & Treasurer · Jan 8, 2016 – Jan 2, 2018 · Past |
| Christopher D Galloway | Chief Medical Officer · Oct 19, 2020 – Jan 27, 2022 · Past |
| Craig Abolin | VP of Research & Dev - Subsid. · Nov 18, 2013 – Jun 3, 2014 · Past |
| David G Kalergis | Chairman and CEO, Director · Jan 8, 2016 – Jan 2, 2020 · Past |
| David Quigley | Senior Partner · Since at least Oct 27, 2025 |
| David Randolph Jones | Chief Medical Officer · Jan 8, 2016 – Jan 8, 2016 · Past |
| Diana M Lanchoney | Director · Jun 25, 2021 – Jun 30, 2023 · Past |
| Jill Davidson | Director · Jul 26, 2023 – Sep 15, 2023 · Past |
| John William Tanner | Chief Financial Officer · Aug 16, 2023 – Jan 26, 2024 · Past |
| Marco Verwijs | Executive Vice President, Technical Operations · Since at least Mar 4, 2026 |
| Mark A Weinberg | Sr.V.P.- Clinical Development · Aug 4, 2014 – Aug 4, 2014 · Past |
| Mark De Rosch | Executive Vice President, Regulatory and Government Affairs, and Program Management · Since at least May 1, 2025 |
| Mark T Giles | Director · Jan 8, 2016 – Jul 1, 2021 · Past |
| Marwan Sabbagh | Director · Since at least Aug 16, 2023 |
| Mike Dunleavy Sr | Director · Oct 15, 2009 – Oct 15, 2009 · Past |
| Nelson K Stacks | Director · Nov 18, 2013 – Jul 24, 2014 · Past |
| PJ Kelleher | Investor Relations · Since at least Dec 4, 2025 |
| Robert Joseph Cobuzzi Jr | Chief Operating Officer · Jan 7, 2020 – Feb 4, 2025 · Past |
| Robert W Adams | Director · Jan 8, 2016 – Jul 1, 2021 · Past |
| Thomas E Byrne | General Counsel · Jan 8, 2016 – Jan 7, 2020 · Past |
| William Elder | Chief Financial Officer and General Counsel · Since at least Sep 22, 2020 |
Log in to ask 6ix AI your own questions about CervoMed Inc.